Trinity Biotech Names GraficaGroup Agency of Record
22 June 2005 - 12:17AM
PR Newswire (US)
Trinity Biotech Names GraficaGroup Agency of Record Grafica
Supporting Clinical Diagnostic Instrumentation Marketing in
Hemostasis, Immunodiagnostics, and Rapid HIV Testing CHESTER, N.J.,
June 21 /PRNewswire/ -- Today, GraficaGroup officially announced
that Trinity Biotech USA has named the Chester-based company as its
new Agency of Record. After reviewing several agencies in the first
quarter of 2005, Trinity selected Grafica to help develop and
communicate a new brand position to support an overall
marketing-communications campaign. Grafica will provide
advertising, media, trade-show support, and interactive services
for Trinity, as the company continues its growth and expansion
within multiple clinical diagnostic markets, including hemostasis,
immunodiagnostics, specialty chemistry, and rapid HIV testing.
"After establishing our U.S. headquarters in New Jersey this year,
we sought an agency that could help position the Trinity brand and
tell the Trinity story to our key markets," said Philippe Gadal,
Ph.D., U.S. CEO, Trinity Biotech. "Grafica proved they possess the
requisite creative talent and branding experience that Trinity
needs to effectively promote our products, technology, and service,
as we continue growing business and market share in the United
States." Grafica began its relationship with Trinity by developing
a new brand position, print advertisement, and tagline: Diagnostics
Driven by Life.(R) The campaign starts in June in several
publications targeting clinical diagnostic professionals and public
health officials. The new Trinity campaign conveys how Trinity
understands the pressures of life in the laboratory, while
communicating the well-known brands in the company's portfolio,
which includes AMAX Destiny(TM) (coagulation), NEXGEN Four
(infectious disease), and the Uni-Gold(TM) Recombigen(R) rapid HIV
test. "Trinity's products greatly improve the way diagnostic
laboratories function, and its Uni-Gold product is the fastest and
simplest test for detecting HIV infection," said Debra Taeschler,
President and CEO, GraficaGroup. "We at Grafica look forward to
integrating the brand position we developed for Trinity across
multiple media, including the Web, which we believe will help
Trinity assume market leadership in hemostasis, infectious disease,
clinical chemistry, and rapid HIV testing." About Trinity Biotech
USA With its U.S. Corporate Headquarters based in Berkeley Heights,
New Jersey, Trinity Biotech Inc. is a wholly owned subsidiary of
Trinity Biotech plc (NASDAQ:TRIB). With World Headquarters in Bray,
Ireland, Trinity Biotech plc was established in 1992. Through an
acquisition-growth strategy, Trinity has acquired companies with
expertise in the development and commercialization of both
instrumentation and reagents primarily servicing the infectious
disease, hemostasis, specialty chemistry, and HIV diagnostics
markets. Additional information about Trinity is available on the
company Web site at http://www.trinitybiotech.com/. About
GraficaGroup GraficaGroup is a full-service, fully integrated
advertising agency led by professionals from Madison Avenue who
continue to craft brand -- and relationship-building campaigns from
just off of Main Street in Chester, New Jersey. Grafica
(http://www.grafica.com/) provides both traditional and online
marketing campaigns, including broadcast, print, out of home,
direct mail, point of purchase, email, and Web-site design and
development. Grafica also offers media planning and buying,
search-engine optimization, database management, and public
relations. Clients include AT&T, Cathedral Healthcare System,
First Morris Bank and Trust, Horizon Blue Cross Blue Shield of New
Jersey, Jackson Hewitt Tax Service, the New Jersey Board of Public
Utilities, the New Jersey Office of the Attorney General,
PSE&G, Singer Nelson Charlmers, Synchronoss Technologies, and
Wells Fargo Home Mortgage. Forward-Looking Statements
Forward-looking statements in this release are made pursuant to the
"safe harbor" provision of the Private Securities Litigation Reform
Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, but not
limited to, the results of research and development efforts, the
effect of regulation by the United States Food and Drug
Administration and other agencies, the impact of competitive
products, product development commercialization and technological
difficulties, and other risks detailed in the Company's periodic
reports filed with the Securities and Exchange Commission. Contact:
Dana Thomas Trinity Biotech USA 908.898.1500 x7010 Mark Devaney
GraficaGroup 908.879.2169 x115 DATASOURCE: GraficaGroup CONTACT:
Dana Thomas of Trinity Biotech USA, +1-908-898-1500 ext. 7010, ; or
Mark Devaney of GraficaGroup, +1-908-879-2169, ext. 115, Web site:
http://www.grafica.com/ http://www.trinitybiotech.com/
Copyright